查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1827881

放射性藥物市場（按放射性同位素類型、生產技術、應用和最終用戶分類）—2025-2032 年全球預測

Radiopharmaceuticals Market by Radioisotope Type, Production Technology, Application, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年放射性藥物市場將成長至 91.9 億美元，複合年成長率為 6.67%。

主要市場統計數據
基準年2024年 54.8億美元
預計2025年 58.4億美元
預測年份：2032年 91.9億美元
複合年成長率（%） 6.67%

簡要概述當今放射性藥物環境，重點關注影響產業決策的技術、臨床需求和策略重點

全球放射性藥物產業正處於技術加速演進和策略重新定位的時期。同位素製造和自動化領域的最新創新正在降低許多臨床和研究終端用戶的複雜性，同時，多個治療領域日益成長的臨床需求也加劇了人們對供應鏈韌性和監管協調的關注。隨著產業相關人員重新評估籌資策略和資本配置，他們需要一個簡潔的、以證據為基礎的綜合方案，將技術、臨床應用和終端使用者能力整合到一個切實可行的決策框架中。

本執行摘要將複雜的發展格局綜合成切實可行的見解，重點闡述了生產模式、同位素多樣性和特定應用動態如何共同塑造營運重點。本書整理了影響投資、夥伴關係和商業化的關鍵趨勢，並重點闡述了其對製造商、臨床服務供應商和政策制定者的影響。引言著重於結構性促進因素而非推測性預測，從而將後續分析建立在技術採用、監管態勢和臨床需求模式的可觀察變化之上。因此，讀者可以清楚地評估短期和中期策略重點。

分散的同位素製造、治療診斷學動力和監管清晰度如何重塑放射性藥物的臨床取得和商業性機會

放射性藥物產業正在經歷一場變革性的轉變，這得益於放射性同位素生產的創新、治療診斷學的進步以及針對性臨床應用的依證的不斷拓展。迴旋加速器效率和緊湊型發生器系統的進步正在分散關鍵同位素的獲取，使地方醫院和診斷中心能夠探索以前只有大型學術中心才能使用的現場或近現場生產模式。同時，透過先進的合成模組實現的自動化正在縮短週轉時間、提高可重複性，並在更嚴格的監管要求下實現更高的產量。

診療方法正在提升某些放射性核種的商業性和臨床價值，並促進分子影像公司、藥物開發商和契約製造之間建立策略聯盟。腫瘤學和神經病學臨床試驗的擴展進一步支持了這種融合，這些試驗正在產生可靠的資料集，為報銷討論和臨床應用提供資訊。此外，監管機構擴大發布指導意見，明確新型放射性配體的製造品質要求，如果申辦方能夠滿足這些標準，則可以降低規模化的門檻。總體而言，整個格局正在轉向一個更分散但以品質為導向的生態系統，其中敏捷性、製造可靠性和臨床證據是關鍵的競爭優勢。

2025 年美國關稅的最新發展將如何推動放射性藥物相關人員的供應鏈重組、近岸外包和庫存策略變化

2025年關稅的實施以及美國貿易政策的轉變，相關人員依賴跨境供應鏈獲取前驅物、設備和成品放射性藥物的利害關係人帶來了額外的複雜性。進口關稅和合規流程增加了從國際供應商採購專用零件的成本和行政負擔，促使許多組織重新評估其供應商基礎和物流策略。為此，一些製造商和臨床網路正在加速近岸外包和垂直整合，以減輕關稅波動的影響，並確保關鍵同位素和耗材的供應連續性。

同時，過渡期的關稅摩擦和更嚴格的產品分類延長了某些進口產品的前置作業時間，促使企業增加庫存緩衝和合約應急準備金。因此，採購團隊更重視可行的國內供應方案、多源採購策略以及發展本地製造能力。這些調整反過來又影響了資本規劃、生產資產位置和策略儲備方面的決策。整體而言，關稅環境正在推動企業重新思考供應鏈的穩健性，迫使企業在成本壓力和不間斷臨床交付需求之間取得平衡。

細分主導的可操作見解，將同位素特性、生產模式、臨床應用和最終用戶業務實踐與策略性投資選擇連結起來

細分領域的情報揭示了指南產品開發、商業化和營運投資的差異化動態。根據放射性同位素類型，氟-18、鎵-68、碘-131、Technetium鎦的臨床和物流概況在生產調度、低溫運輸管理和監管文件方面各有不同考慮。根據生產技術，在自動化合成模組、迴旋加速器、發電機和核子反應爐生產之間的選擇，會在資本強度、產量和地理靈活性之間產生權衡，這些權衡應反映在網路設計和資本配置決策中。

目錄

第1章 引言

第2章分析方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 鎦-177 PSMA療法的擴展正在推動對高純度放射性核素供應的需求
  • 採用自動化和微流體合成模組進行現場放射性藥物製造
  • 監管協調努力加速跨地區胜肽受體放射性核素治療的核准
  • 生技公司與迴旋加速器製造商建立策略夥伴關係，提高鎵-68的供應
  • 透過整合人工智慧驅動的劑量測定平台實現放射性藥物治療通訊協定的個人化
  • 針對難治性惡性腫瘤的α放射藥物的出現
  • 投資冷套件配方，方便製備Technetium-99m放射性示蹤劑

第6章：美國關稅的累積影響（2025年）

第7章：人工智慧（AI）的累積影響（2025年）

第 8 章：放射性藥物市場（依放射性同位素類型）

  • 氟18
  • 鎵-68
  • 碘-131
  • 鎦-177
  • Technetium-99m

第9章放射性藥物市場（依生產技術）

  • 自動合成模組
  • 迴旋加速器基地
  • 發電機底座
  • 核子反應爐底座

第 10 章放射性藥物市場（依應用）

  • 心臟病
  • 內分泌失調
  • 神經系統疾病
  • 瘤

第 11 章 放射性藥物市場（依最終使用者）

  • 診所
  • 診斷中心
  • 醫院
  • 研究所

第12章放射性藥物市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章放射性藥物市場（依類別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 各國放射性藥物市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章競爭格局

  • 市佔率分析（2024年）
  • FPNV定位矩陣（2024年）
  • 競爭分析
    • Curium NV
    • Lantheus Holdings, Inc.
    • Cardinal Health, Inc.
    • Eckert & Ziegler AG
    • Jubilant Pharmova Limited
    • GE HealthCare Technologies Inc.
    • Bayer AG
    • Novartis AG
    • Nordion Inc.
    • Ion Beam Applications SA
Product Code: MRR-4308E1C887A3

The Radiopharmaceuticals Market is projected to grow by USD 9.19 billion at a CAGR of 6.67% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 5.48 billion
Estimated Year [2025] USD 5.84 billion
Forecast Year [2032] USD 9.19 billion
CAGR (%) 6.67%

A succinct orientation to today's radiopharmaceutical environment highlighting technology, clinical demand, and strategic priorities shaping industry decisions

The global radiopharmaceutical landscape is undergoing a period of accelerated technological evolution and strategic repositioning. Recent innovations in isotope production and automation have reduced complexity for many clinical and research end users, while rising clinical demand across multiple therapeutic areas has intensified attention on supply chain resilience and regulatory alignment. As industry stakeholders reassess procurement strategies and capital allocation, they require concise, evidence-based synthesis that links technology, clinical application, and end-user capacity to practical decision frameworks.

This executive summary synthesizes complex developments into actionable insight, emphasizing how production modalities, isotope diversity, and application-specific dynamics converge to shape operational priorities. It frames the major trends influencing investment, partnerships, and commercialization, while clarifying implications for manufacturers, clinical service providers, and policy makers. By focusing on structural drivers rather than speculative projections, the introduction grounds subsequent analysis in observable shifts in technology adoption, regulatory posture, and clinical demand patterns. Consequently, readers will gain a clear starting point for evaluating where to focus strategic effort in the near and medium term.

How decentralization of isotope production, theranostics momentum, and regulatory clarity are reshaping clinical access and commercial opportunity for radiopharmaceuticals

The radiopharmaceutical sector is experiencing transformative shifts driven by innovation in radioisotope production, advances in theranostics, and an expanding evidence base for targeted clinical applications. Developments in cyclotron efficiency and compact generator systems are decentralizing access to key isotopes, enabling community hospitals and diagnostic centers to contemplate onsite or near-site production models where previously only large academic centers could participate. At the same time, automation through advanced synthesis modules is reducing hands-on time, improving reproducibility, and enabling higher throughput under tighter regulatory requirements.

Theranostic approaches have elevated the commercial and clinical value of certain radionuclides, prompting strategic partnerships between molecular imaging companies, pharmaceutical developers, and contract manufacturers. This convergence is further supported by expanding clinical trials in oncology and neurology, which are generating robust datasets that inform reimbursement discussions and clinical adoption. Additionally, regulatory authorities are increasingly issuing guidance that clarifies manufacturing quality expectations for novel radioligands, thereby lowering barriers to scale when sponsors can meet these standards. Overall, the landscape is moving toward a more distributed yet quality-focused ecosystem, where agility, manufacturing reliability, and clinical evidence become decisive competitive differentiators.

How recent United States tariff developments in 2025 are prompting supply chain reconfiguration, nearshoring, and inventory strategy changes across radiopharmaceutical stakeholders

The introduction of tariffs and trade policy shifts in the United States in 2025 has introduced an additional layer of complexity for stakeholders that depend on cross-border supply chains for precursors, equipment, and finished radiopharmaceuticals. Import duties and compliance processes have increased the cost and administrative burden associated with sourcing specialized components from international suppliers, which has prompted many organizations to reevaluate their supplier base and logistics strategies. In response, several manufacturers and clinical networks have accelerated nearshoring and vertical integration efforts to reduce exposure to tariff volatility and to secure continuity of supply for critical isotopes and consumables.

Meanwhile, transitional frictions in customs clearance and increased scrutiny of product classification have lengthened lead times for certain imported goods, encouraging greater inventory buffers and contractual contingencies. As a result, procurement teams are placing greater emphasis on validated domestic supply options, multi-sourcing strategies, and the development of in-region manufacturing capabilities. These adjustments, in turn, influence capital planning, site selection for production assets, and decisions regarding strategic stockpiles. In sum, the tariff environment has catalyzed a rethink of supply chain robustness, compelling organizations to balance cost pressures with the imperative of uninterrupted clinical delivery.

Actionable segmentation-driven insights linking isotope characteristics, production modalities, clinical applications, and end-user operating realities to strategic investment choices

Segment-level intelligence reveals differentiated dynamics that should guide product development, commercialization, and operational investments. Based on Radioisotope Type, the clinical and logistical profiles of Fluorine-18, Gallium-68, Iodine-131, Lutetium-177, and Technetium-99m each present distinct considerations for production scheduling, cold chain management, and regulatory documentation, which means manufacturers must align capacity and quality systems to the decay characteristics andhandling constraints of each isotope. Based on Production Technology, choices between Automated Synthesis Modules, Cyclotron Based, Generator Based, and Reactor Based production create trade-offs between capital intensity, throughput, and geographic flexibility, and these trade-offs should inform network design and capital allocation decisions.

Based on Application, the clinical pathways and reimbursement trajectories vary significantly across Cardiology, Endocrinology, Neurology, and Oncology, so commercial teams must tailor evidence generation and payer engagement strategies to the clinical value propositions relevant to each specialty. Based on End User, operational and service models differ between Clinics, Diagnostic Centres, Hospitals, and Research Institutes, affecting demand patterns, procurement lead times, and the types of service agreements that will be most compelling. Taken together, these segmentation lenses enable organizations to prioritize investments in production technology and clinical evidence according to the intersection of isotope attributes, manufacturing capabilities, therapeutic use cases, and end-user operating realities. Consequently, segmentation-driven strategies will be central to achieving operational efficiency and commercial traction.

How regional infrastructure, regulatory diversity, and clinical priorities across the Americas, Europe, Middle East & Africa, and Asia-Pacific determine access models and strategic partnerships

Regional dynamics shape both supply-side strategic choices and the pathways for clinical adoption. In the Americas, investment in advanced cyclotron infrastructure and a dense network of hospitals and diagnostic centers create a favorable environment for scaling production of short-lived isotopes and for piloting decentralized models that bring imaging and therapeutic radionuclides closer to patients. Conversely, regulatory harmonization and reimbursement variability across jurisdictions require tailored market-entry approaches and close engagement with regional payers to secure adoption.

In Europe, Middle East & Africa, diverse regulatory regimes and variable access to capital mean that partnerships and contract manufacturing arrangements are often the most efficient route to expand clinical availability, while regional hubs with reactor or cyclotron capacity continue to supply neighboring markets. Many countries in this region are actively investing in capability building, which opens opportunities for technology transfer and training programs. In the Asia-Pacific region, rapid expansion of clinical imaging infrastructure and strong government support for biotechnology have accelerated local production capabilities and interest in theranostic agents, yet fragmented regulatory pathways and differing clinical practice patterns require nuanced market access strategies. Across regions, cross-border collaboration, supply chain redundancy, and targeted clinical evidence programs remain essential to manage operational risk and to accelerate patient access.

Competitive strategies shaping the sector including vertical integration, partnerships for theranostics, automation investments, and contract manufacturing expansion

Leading industry participants are differentiating themselves through a combination of vertical integration, strategic partnerships, and focused investments in automation and quality systems. Some organizations are investing in modular, scalable production assets to support decentralized delivery models, while others pursue collaborations with pharmaceutical developers to co-develop theranostic compounds and companion diagnostics. In parallel, contract development and manufacturing providers are expanding service portfolios to include fill-finish, radiolabeling, and supply chain management services that address specific pain points for both small biotech innovators and established manufacturers.

Strategic M&A and licensing arrangements are also reshaping competitive positioning, enabling faster access to new isotopes, intellectual property, and distribution networks without the lead time associated with greenfield production. Equally important, companies that invest early in automation of synthesis modules and in robust quality-by-design approaches are achieving greater reproducibility and regulatory readiness, which can shorten time-to-market for novel radioligands. Finally, alliances with clinical networks and academic centers support evidence generation while providing pathways for real-world performance data that inform reimbursement and guideline inclusion decisions. Collectively, these company-level tactics illustrate how operational capability, strategic partnerships, and evidence generation are being used to build defensible market positions.

A focused set of practical strategic moves for industry leaders to fortify supply chains, accelerate clinical adoption, and secure competitive advantage in radiopharmaceuticals

Industry leaders should prioritize a set of practical, high-impact actions to strengthen resilience and commercial potential. First, accelerate evaluation of production footprints with an emphasis on modular, scalable assets that support decentralized delivery for short-lived isotopes, integrating automation where it reduces variability and labor intensity. Second, pursue selective nearshoring or regional partnerships to mitigate tariff exposure and to shorten logistical pathways, while also establishing multi-sourcing agreements for critical precursors and consumables to reduce single-source risk.

Third, align clinical evidence generation with payer expectations by designing trials and real-world evidence programs that demonstrate clear clinical utility in Cardiology, Endocrinology, Neurology, and Oncology, investing in health economic models that translate clinical outcomes into value propositions for payers. Fourth, deepen collaborations with hospitals, diagnostic centres, clinics, and research institutes to pilot service models and to gather implementation data that improves uptake. Finally, strengthen regulatory and quality frameworks early in development to ensure readiness for diverse market requirements, and invest in workforce training to support operational resilience. Taken together, these actions will help organizations convert market insight into durable operational and commercial advantage.

Transparent and reproducible research processes combining expert interviews, technical validation, and literature synthesis to deliver actionable radiopharmaceutical insights

The research underpinning this executive summary synthesizes primary and secondary sources to deliver an evidence-based perspective while maintaining methodological transparency. Primary inputs include structured interviews with manufacturing leaders, clinical directors, and supply chain managers, as well as technical consultations with experts in cyclotron operations, generator technology, and automated synthesis. Secondary sources include regulatory guidance, peer-reviewed clinical literature, and operational data from production facilities that inform assessments of throughput, quality systems, and logistics practices.

Analytical methods employed qualitative triangulation to reconcile differing stakeholder perspectives and technical validation to ensure consistency with known decay and handling constraints for each isotope. Where appropriate, case examples were used to illustrate operational approaches without extrapolating into specific market sizing or forecasting. Throughout the research process, emphasis was placed on reproducibility and practical relevance, and findings were reviewed by independent subject-matter experts to ensure that conclusions reflect current technological capabilities, regulatory trends, and observable shifts in clinical adoption.

Concluding synthesis emphasizing resilience, evidence-driven adoption, and strategic capability building as the decisive factors for future success in radiopharmaceuticals

In conclusion, the radiopharmaceutical sector is evolving toward a more distributed, evidence-driven, and quality-centric model. Advances in production technologies and automation are enabling a diversification of manufacturing footprints, while the growth of theranostics is creating new pathways for clinical and commercial collaboration. At the same time, policy changes and trade measures are prompting a re-evaluation of supply chain design and procurement strategies, underscoring the importance of resilience and operational flexibility.

For decision-makers, the implications are clear: invest in adaptable production capabilities, prioritize emission of high-quality clinical evidence tailored to specific therapeutic areas, and cultivate regional partnerships that mitigate logistical and regulatory friction. By doing so, organizations can not only manage near-term disruptions but also position themselves to capture long-term clinical and commercial opportunities as the radiopharmaceutical ecosystem matures. These choices will materially influence the pace at which new diagnostics and therapeutics reach patients and will determine which organizations lead in an increasingly complex and competitive environment.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Expansion of Lutetium-177 PSMA therapies driving demand for high-purity radionuclide supply
  • 5.2. Adoption of automation and microfluidic synthesis modules for on-site radiopharmaceutical production
  • 5.3. Regulatory harmonization efforts accelerating approval of peptide receptor radionuclide therapy across regions
  • 5.4. Strategic partnerships between biotech firms and cyclotron manufacturers to improve Gallium-68 availability
  • 5.5. Integration of AI-driven dosimetry platforms to personalize radiopharmaceutical treatment protocols
  • 5.6. Emergence of alpha-emitting radiopharmaceuticals targeting refractory malignancies with targeted therapy
  • 5.7. Investments in cold kit formulations enabling simplified preparation of technetium-99m radiotracers

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Radiopharmaceuticals Market, by Radioisotope Type

  • 8.1. Fluorine-18
  • 8.2. Gallium-68
  • 8.3. Iodine-131
  • 8.4. Lutetium-177
  • 8.5. Technetium-99m

9. Radiopharmaceuticals Market, by Production Technology

  • 9.1. Automated Synthesis Modules
  • 9.2. Cyclotron Based
  • 9.3. Generator Based
  • 9.4. Reactor Based

10. Radiopharmaceuticals Market, by Application

  • 10.1. Cardiology
  • 10.2. Endocrinology
  • 10.3. Neurology
  • 10.4. Oncology

11. Radiopharmaceuticals Market, by End User

  • 11.1. Clinics
  • 11.2. Diagnostic Centres
  • 11.3. Hospitals
  • 11.4. Research Institutes

12. Radiopharmaceuticals Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Radiopharmaceuticals Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Radiopharmaceuticals Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Curium NV
    • 15.3.2. Lantheus Holdings, Inc.
    • 15.3.3. Cardinal Health, Inc.
    • 15.3.4. Eckert & Ziegler AG
    • 15.3.5. Jubilant Pharmova Limited
    • 15.3.6. GE HealthCare Technologies Inc.
    • 15.3.7. Bayer AG
    • 15.3.8. Novartis AG
    • 15.3.9. Nordion Inc.
    • 15.3.10. Ion Beam Applications SA

LIST OF FIGURES

  • FIGURE 1. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS RADIOPHARMACEUTICALS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA RADIOPHARMACEUTICALS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. RADIOPHARMACEUTICALS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. RADIOPHARMACEUTICALS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. RADIOPHARMACEUTICALS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY FLUORINE-18, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY FLUORINE-18, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY FLUORINE-18, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY FLUORINE-18, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY FLUORINE-18, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY FLUORINE-18, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY GALLIUM-68, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY GALLIUM-68, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY GALLIUM-68, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY GALLIUM-68, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY GALLIUM-68, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY GALLIUM-68, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY IODINE-131, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY IODINE-131, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY IODINE-131, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY IODINE-131, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY IODINE-131, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY IODINE-131, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY LUTETIUM-177, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY LUTETIUM-177, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY LUTETIUM-177, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY LUTETIUM-177, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY LUTETIUM-177, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY LUTETIUM-177, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY TECHNETIUM-99M, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY TECHNETIUM-99M, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY TECHNETIUM-99M, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY TECHNETIUM-99M, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY TECHNETIUM-99M, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY TECHNETIUM-99M, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY AUTOMATED SYNTHESIS MODULES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY AUTOMATED SYNTHESIS MODULES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY AUTOMATED SYNTHESIS MODULES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY AUTOMATED SYNTHESIS MODULES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY AUTOMATED SYNTHESIS MODULES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY AUTOMATED SYNTHESIS MODULES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY CYCLOTRON BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY CYCLOTRON BASED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY CYCLOTRON BASED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY CYCLOTRON BASED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY CYCLOTRON BASED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY CYCLOTRON BASED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY GENERATOR BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY GENERATOR BASED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY GENERATOR BASED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY GENERATOR BASED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY GENERATOR BASED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY GENERATOR BASED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY REACTOR BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY REACTOR BASED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY REACTOR BASED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY REACTOR BASED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY REACTOR BASED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY REACTOR BASED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY CARDIOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY CARDIOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY CARDIOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY CARDIOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY CARDIOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY ENDOCRINOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY ENDOCRINOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY ENDOCRINOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY ENDOCRINOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY ENDOCRINOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY ENDOCRINOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC CENTRES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC CENTRES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC CENTRES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC CENTRES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC CENTRES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC CENTRES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. AMERICAS RADIOPHARMACEUTICALS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 118. AMERICAS RADIOPHARMACEUTICALS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 119. AMERICAS RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2018-2024 (USD MILLION)
  • TABLE 120. AMERICAS RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2025-2032 (USD MILLION)
  • TABLE 121. AMERICAS RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 122. AMERICAS RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 123. AMERICAS RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 124. AMERICAS RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 125. AMERICAS RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 126. AMERICAS RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. NORTH AMERICA RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2018-2024 (USD MILLION)
  • TABLE 130. NORTH AMERICA RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2025-2032 (USD MILLION)
  • TABLE 131. NORTH AMERICA RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 132. NORTH AMERICA RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 134. NORTH AMERICA RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 136. NORTH AMERICA RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. LATIN AMERICA RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2018-2024 (USD MILLION)
  • TABLE 140. LATIN AMERICA RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2025-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 142. LATIN AMERICA RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 144. LATIN AMERICA RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 145. LATIN AMERICA RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 146. LATIN AMERICA RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA RADIOPHARMACEUTICALS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA RADIOPHARMACEUTICALS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2018-2024 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2025-2032 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 157. EUROPE RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. EUROPE RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. EUROPE RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2018-2024 (USD MILLION)
  • TABLE 160. EUROPE RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2025-2032 (USD MILLION)
  • TABLE 161. EUROPE RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 162. EUROPE RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 163. EUROPE RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 164. EUROPE RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 165. EUROPE RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 166. EUROPE RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 167. MIDDLE EAST RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. MIDDLE EAST RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. MIDDLE EAST RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2018-2024 (USD MILLION)
  • TABLE 170. MIDDLE EAST RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2025-2032 (USD MILLION)
  • TABLE 171. MIDDLE EAST RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 172. MIDDLE EAST RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 173. MIDDLE EAST RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 174. MIDDLE EAST RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 175. MIDDLE EAST RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 176. MIDDLE EAST RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 177. AFRICA RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. AFRICA RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. AFRICA RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2018-2024 (USD MILLION)
  • TABLE 180. AFRICA RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2025-2032 (USD MILLION)
  • TABLE 181. AFRICA RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 182. AFRICA RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 183. AFRICA RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 184. AFRICA RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 185. AFRICA RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 186. AFRICA RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 187. ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2018-2024 (USD MILLION)
  • TABLE 190. ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2025-2032 (USD MILLION)
  • TABLE 191. ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 192. ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 193. ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 194. ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 195. ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 196. ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 199. ASEAN RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. ASEAN RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. ASEAN RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2018-2024 (USD MILLION)
  • TABLE 202. ASEAN RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2025-2032 (USD MILLION)
  • TABLE 203. ASEAN RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 204. ASEAN RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 205. ASEAN RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 206. ASEAN RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 207. ASEAN RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 208. ASEAN RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 209. GCC RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. GCC RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. GCC RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2018-2024 (USD MILLION)
  • TABLE 212. GCC RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2025-2032 (USD MILLION)
  • TABLE 213. GCC RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 214. GCC RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 215. GCC RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 216. GCC RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 217. GCC RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 218. GCC RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPEAN UNION RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPEAN UNION RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 221. EUROPEAN UNION RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPEAN UNION RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2025-2032 (USD MILLION)
  • TABLE 223. EUROPEAN UNION RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPEAN UNION RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPEAN UNION RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPEAN UNION RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 227. EUROPEAN UNION RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPEAN UNION RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 229. BRICS RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 230. BRICS RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 231. BRICS RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2018-2024 (USD MILLION)
  • TABLE 232. BRICS RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2025-2032 (USD MILLION)
  • TABLE 233. BRICS RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 234. BRICS RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 235. BRICS RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 236. BRICS RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 237. BRICS RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 238. BRICS RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 239. G7 RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. G7 RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. G7 RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2018-2024 (USD MILLION)
  • TABLE 242. G7 RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2025-2032 (USD MILLION)
  • TABLE 243. G7 RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 244. G7 RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 245. G7 RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 246. G7 RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 247. G7 RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 248. G7 RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 249. NATO RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 250. NATO RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 251. NATO RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2018-2024 (USD MILLION)
  • TABLE 252. NATO RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2025-2032 (USD MILLION)
  • TABLE 253. NATO RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 254. NATO RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 255. NATO RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 256. NATO RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 257. NATO RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 258. NATO RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 261. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2018-2024 (USD MILLION)
  • TABLE 262. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2025-2032 (USD MILLION)
  • TABLE 263. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 264. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 265. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 266. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 267. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 268. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 269. CANADA RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2018-2024 (USD MILLION)
  • TABLE 270. CANADA RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2025-2032 (USD MILLION)
  • TABLE 271. CANADA RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 272. CANADA RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 273. CANADA RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 274. CANADA RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 275. CANADA RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 276. CANADA RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 277. MEXICO RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2018-2024 (USD MILLION)
  • TABLE 278. MEXICO RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2025-2032 (USD MILLION)
  • TABLE 279. MEXICO RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 280. MEXICO RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 281. MEXICO RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 282. MEXICO RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 283. MEXICO RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 284. MEXICO RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 285. BRAZIL RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2018-2024 (USD MILLION)
  • TABLE 286. BRAZIL RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2025-2032 (USD MILLION)
  • TABLE 287. BRAZIL RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 288. BRAZIL RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 289. BRAZIL RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 290. BRAZIL RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 291. BRAZIL RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 292. BRAZIL RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 293. UNITED KINGDOM RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2018-2024 (USD MILLION)
  • TABLE 294. UNITED KINGDOM RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2025-2032 (USD MILLION)
  • TABLE 295. UNITED KINGDOM RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 296. UNITED KINGDOM RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 297. UNITED KINGDOM RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 298. UNITED KINGDOM RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 299. UNITED KINGDOM RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 300. UNITED KINGDOM RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 301. GERMANY RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2018-2024 (USD MILLION)
  • TABLE 302. GERMANY RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2025-2032 (USD MILLION)
  • TABLE 303. GERMANY RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 304. GERMANY RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 305. GERMANY RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 306. GERMANY RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 307. GERMANY RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 308. GERMANY RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 309. FRANCE RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2018-2024 (USD MILLION)
  • TABLE 310. FRANCE RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2025-2032 (USD MILLION)
  • TABLE 311. FRANCE RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 312. FRANCE RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 313. FRANCE RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 314. FRANCE RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 315. FRANCE RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 316. FRANCE RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 317. RUSSIA RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2018-2024 (USD MILLION)
  • TABLE 318. RUSSIA RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2025-2032 (USD MILLION)
  • TABLE 319. RUSSIA RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 320. RUSSIA RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 321. RUSSIA RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 322. RUSSIA RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 323. RUSSIA RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 324. RUSSIA RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 325. ITALY RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2018-2024 (USD MILLION)
  • TABLE 326. ITALY RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2025-2032 (USD MILLION)
  • TABLE 327. ITALY RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 328. ITALY RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 329. ITALY RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 330. ITALY RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 331. ITALY RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 332. ITALY RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 333. SPAIN RADIOPHARMACEUTICA